PET Imaging Study on Occupancy of Dopamine D2 Receptors and Genotypes After Bupropion Administration
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||[11C] Raclopride PET Imaging Study That Investigates Relation Between Occupancy of Dopamine D2 Receptors and Genotypes of DRD2 After Bupropion Administration|
- Dopamine receptor occupancy [ Time Frame: 1 week ] [ Designated as safety issue: No ]
- Pharmacokinetic parameters of bupropion and hydroxybupropion [ Time Frame: 1 week ] [ Designated as safety issue: No ]
|Study Start Date:||November 2008|
|Study Completion Date:||June 2009|
|Primary Completion Date:||March 2009 (Final data collection date for primary outcome measure)|
DRD2 Taq1A1 allele
DRD Taq1 A2 homozygote2
Open, one arm, single sequence, 2-period, study stratified into 2 DRD2 genotype groups For subjects who volunteer to cease smoking, genotypes are investigated. Twelve subjects are enrolled (6 - DRD2 Taq1A1 allele, 6 - DRD2 Taq1A2 homozygotes). Subjects receive baseline raclopride PET (High Specific Activity, Low Specific Activity).
- Period 1 Subjects receive 150 mg of bupropion SR every day. After 1 week of medication, pharmacokinetic and PET studies are performed.
- Period 2 Subjects receive 150 mg of bupropion SR twice a day. After 1 week of medication, pharmacokinetic and PET studies are performed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00846339
|Korea, Republic of|
|Seoul National University Hospital|
|Seoul, Korea, Republic of, 110-744|
|Principal Investigator:||Kyung-Sang Yu, MD||Seoul National Univeristy Hospital|